Category

News

PamGene attains IVDD registration for its IOpener®-NSCLC immunotherapy guidance test in Europe

‘s-Hertogenbosch, the Netherlands, July 21, 2022 PamGene International B.V., an in-vitro diagnostics and biomarker services company developing blood-based immunotherapy guidance tests, today announced its IOpener®-NSCLC test has been registered as...
Read More

PamGene attains IVDD registration for its IOpener®-melanoma immunotherapy guidance test in Europe

‘s-Hertogenbosch, the Netherlands, July 5th, 2022 PamGene International B.V., an in-vitro diagnostics and biomarker services company developing blood-based immunotherapy guidance tests, today announced its IOpener®-melanoma test has been registered as...
Read More

PamGene receives ISO 13485:2016 from DEKRA Certification B.V. for its IOpener® immunotherapy response prediction test devices

‘s-Hertogenbosch, the Netherlands, March 29th, 2022 PamGene International B.V., an in-vitro diagnostics company focused on the development and commercialization of blood-based immunotherapy response prediction tests, today announced it has received...
Read More

Meet our specialists – Savithri Rangarajan

“Making the most out of kinase activity data to take scientific research to the next level is what gets me excited” PamGene’s kinase activity profiling data provides scientists with new...
Read More

Review paper: The past and current trends of kinase research and use of high-throughput active kinome technologies

Recently the University of Toledo published a review paper in ‘The current opinion in pharmacology’. In this review, the authors examine the past and current trends of kinase research and...
Read More

Meet our specialists – Frank de Bruijn

The PamStation is at the core of PamGene’s technology. This fully automated instrument is designed for processing PamChip microarrays to measure kinase activity and can be found at universities worldwide....
Read More

Jointly advancing mutation-independent treatment of inherited retinal diseases

transMed is an integrated training network funded by the European Union to train the next generation of scientists in translational medicine. The consortium focuses on bench-to-bedside development of treatments for...
Read More

Meet our specialists | Unraveling disease mechanisms

“My work at PamGene has always been data driven,” tells Rik de Wijn, data scientist and PamGene’s head of diagnostic assay services. De Wijn joined Pamgene in 2002 after completing...
Read More

PamGene and Sanquin announce extended collaboration to enhance development of PamGene’s predictive immunotherapy response tests

PamGene International B.V., a biomarker services company focused on the development of blood-based immunotherapy selection tests, and Sanquin, the not-for-profit blood services provider in the Netherlands, today announced the extension...
Read More

PamGene joins the 8th Drug Discovery Strategic Summit

Meet PamGene at the 8th Drug Discovery Strategic Summit in Amsterdam (November 4 and 5). Our colleagues Tushar Tomar and Martijn Dankers would be happy to discuss how PamGene’s kinase...
Read More
1 2 3 4 5